Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/II HER2+ breast cancer.

被引：0
|
作者：
Limentani, S
Dorval, T
White, S
Curigliano, G
Campone, M
Disis, N
Piccart, M
Cheever, M
Gérard, C
Brichard, VG
Gauducheau, R
机构：
[1] Carolinas Oncol, Charlotte, NC USA
[2] Curie, Paris, France
[3] Austin MC, Heidelberg, Vic, Australia
[4] IEO, Milan, Italy
[5] Univ Washington, Seattle, WA 98195 USA
[6] Bordet, Brussels, Belgium
[7] Corixa Corp, Seattle, WA USA
[8] GlaxoSmithKline Biol, Rixensart, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：170S / 170S
页数：1
相关论文
共 50 条
  • [21] Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer.
    Peacock, NW
    Bearden, J
    Schnell, F
    White, M
    Greco, FA
    Burris, HA
    Barton, JH
    Hainsworth, JD
    Spigel, DR
    Yardley, DA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 54S - 54S
  • [22] An Update of a Phase II Trial of the HER2 Peptide AE37 Vaccine in Breast Cancer Patients To Prevent Recurrence
    Hale, D. F.
    Perez, S.
    Sears, A. K.
    Clifton, G. T.
    Vreeland, T. J.
    Holmes, J. P.
    Ardavanis, A.
    Pistamaltzian, N.
    Reilias, G.
    Ponniah, S.
    Papamichail, M.
    Peoples, G. E.
    Mittendorf, E. A.
    CANCER RESEARCH, 2011, 71
  • [23] A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.
    Webster, D. J.
    Waisman, J.
    Macleod, B.
    Dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L. G.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 107S - 107S
  • [24] Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+advanced stage breast cancer.
    Disis, Mary L.
    Dang, Yushe
    Coveler, Andrew L.
    Higgins, Doreen
    Childs, Jennifer
    Salazar, Lupe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Phase I/II Study of Adoptive T Cell Therapy Following In Vivo Priming with a HER2 Peptide-Based Vaccine in Patients with Stage IV Breast Cancer.
    Parker, S. L.
    Higgins, D. M.
    Childs, J. S.
    Dang, Y.
    Guthrie, K. A.
    Disis, M. L.
    Salazar, L. G.
    Coveler, A.
    CANCER RESEARCH, 2011, 71
  • [26] A phase I trial of the safety and immunogenicity of a multiple antigen vaccine (STEMVAC) in HER2 negative advanced stage breast cancer patients
    Higgins, D. M.
    Childs, J. S.
    Salazar, L. G.
    Disis, M. L.
    CANCER RESEARCH, 2016, 76
  • [27] Relationship between topoisomerase II α (Topo IIα) expression and HER2 status in breast cancer.
    Jacobs, TW
    Pliss, N
    Schnitt, SJ
    LABORATORY INVESTIGATION, 2001, 81 (01) : 28A - 28A
  • [28] A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer
    Cobleigh, MA
    Langmuir, VK
    Sledge, GW
    Miller, KD
    Haney, L
    Novotny, WF
    Reimann, JD
    Vassel, A
    SEMINARS IN ONCOLOGY, 2003, 30 (05) : 117 - 124
  • [29] Relationship between topoisomerase II α (TOPO IIα) expression and HER2 status in breast cancer.
    Jacobs, TW
    Pliss, N
    Schnitt, SJ
    MODERN PATHOLOGY, 2001, 14 (01) : 28A - 28A
  • [30] Phase I dose-escalation trial of ONT-380 in combination with trastuzumab in patients (pts) with HER2+breast cancer brain metastases
    Metzger, O.
    Barry, W.
    Krop, I.
    Guo, H.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R.
    Tolaney, S.
    Winer, E.
    Lin, N.
    CANCER RESEARCH, 2017, 77
12345